Green Banana Peel Extract for Melasma Treatment

Universidade do Vale do Sapucai74 enrolled

Overview

To develop and evaluate a pharmaceutical formula based on green banana peel extract for the treatment of melasma.

Objective: to develop and evaluate a pharmaceutical formula based on green banana peel extract for the treatment of melasma. Methods: it will be a clinical, interventional, longitudinal study, random sampling, Sample will have 60 patients divided into two groups. In the Control Group, SPF 30 sunscreen plus pharmaceutical formulation without green banana peel extract will be used, and in the Study Group, in addition to SPF 30 sunscreen, pharmaceutical formulation containing green banana peel extract will be used. Patients will undergo treatment for 90 days, evaluated every 30 days through clinical evaluation and MELASQol.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

TRIPLE

Enrollment

Conditions

Melasma

Interventions

SPF 30 sunscreen plus pharmaceutical formulation without green banana peel extractBIOLOGICAL

Control Group will use SPF 30 sunscreen plus pharmaceutical formulation without green banana peel extract

SPF 30 sunscreen and pharmaceutical formulation containing green banana peel extractBIOLOGICAL

Study Group In addition to the SPF 30 sunscreen, a pharmaceutical formulation containing green banana peel extract will be used.

Eligibility

Sex: FEMALEMin age: 18 YearsMax age: 60 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Female patients with melasma. * Patients aged 18 years or over and 60 years or less. * Patients who agree to participate in the study. - Exclusion Criteria: * Patients who have other types of facial hyperchromia. * Patients who give up, for any reason, to continue treatment. * Patients who have any type of allergic reaction to the product.

Locations (1)

Vale do Sapucaí University

Pouso Alegre, Minas Gerais, Brazil

Outcomes

Primary Outcomes

Clinical analysis of Melasma

Analysis of the skin affected by Melasma will be performed with Melasma Area Severity Index (MASI), the most commonly used outcome measure for melasma.

Time frame: 3 months

Quality of life analysis

Analysis of the quality of life of Melasma patients during the study will be performed using the MELASQol Instrument. It is a useful tool in assessing quality of life in patients with melasma.

Time frame: 3 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.